Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?

Rashed A. Ghandour, Samuel Kusin, Daniel Wong, Xiaosong Meng, Nirmish Singla, Yuval Freifeld, Aditya Bagrodia, Vitaly Margulis, Arthur Sagalowsky, Yair Lotan, Solomon L. Woldu

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: There is controversy regarding the benefit of a grossly complete transurethral resection of bladder tumor (TURBT) for muscle-invasive bladder cancer (MIBC) in patients prior to neoadjuvant chemotherapy (NAC). Advocates for this approach suggest a higher response rate to NAC, while others suggest this can increase the surgical risk for no clear benefit. Methods: We retrospectively reviewed our institutional radical cystectomy (RC) database from 2011 to 2018 for patients who received an adequate course of cisplatin-based NAC for nonmetastatic MIBC. Univariable and multivariable logistic regression analyses were performed to identify factors associated with complete response [ypT0] or no residual muscle invasive bladder cancer [ypT < 2] following NAC based on clinicopathologic characteristics and grossly complete or incomplete TURBT. Results: A total of 167 patients received NAC followed by RC for MIBC during the study period and 100 patients were included in the analysis due to known status of the completeness of TURBT—of these 49 patients underwent complete resection while 51 patients underwent incomplete resection prior to NAC. There were no significant differences in baseline clinicopathologic characteristics between patients who had complete vs. incomplete TURBT. At the time of RC, the overall ypT0 rate was 24% (n = 24), while the overall rate of ypT < 2 was 45%. On logistic regression, there was no association between completeness of TURBT and ypT0 or ypT < 2. Age, histology, and organ-confined disease were not significantly associated with response to NAC. Only smoking status (current or prior history) was negatively associated with ypT0 on univariable and multivariable analysis (odds ratio = 0.36, 95% confidence interval: [0.14–0.91], P = 0.031). Conclusion: We found no association between response to cisplatin-based NAC and completeness of TURBT in a cohort of MIBC patients. The study is limited by its retrospective nature and lack of ability to predict response to NAC based on TURBT tissue evaluation.

Original languageEnglish (US)
Pages (from-to)736.e11-736.e18
JournalUrologic Oncology: Seminars and Original Investigations
Volume38
Issue number9
DOIs
StatePublished - Sep 2020
Externally publishedYes

Keywords

  • Bladder cancer
  • Complete resection
  • Complete response
  • Muscle invasive
  • Neoadjuvant chemotherapy
  • Transurethral resection

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint

Dive into the research topics of 'Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?'. Together they form a unique fingerprint.

Cite this